Company Directory - AtriCure, Inc.
Company Details - AtriCure, Inc.
AtriCure, Inc.
WebsiteAtriCure, Inc. is a medical device company focused on the development of innovative products for the treatment of atrial fibrillation and other cardiac conditions.
CCI Score
CCI Score: AtriCure, Inc.
4.93
-0.01%
Latest Event
AtriCure 2024 Political Contributions and Lobbying Report
According to OpenSecrets, AtriCure Inc reported $10,331 in political contributions and $22,500 in lobbying expenditures during the 2024 election cycle, reflecting its engagement in political financing and lobbying activities.
Take Action
So what can you do? Support by shopping, spreading the word, or offering your support.
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
OBJECTOR
AtriCure, Inc. is currently rated as an Objector.
Latest Events
- FEB192025
According to OpenSecrets, AtriCure Inc reported $10,331 in political contributions and $22,500 in lobbying expenditures during the 2024 election cycle, reflecting its engagement in political financing and lobbying activities.
-15
Political Contributions and Lobbying Efforts
April 30
The reported figures, though relatively modest, indicate that AtriCure Inc is participating in political financing and lobbying activities. From an anti-fascist perspective, even limited corporate political engagement can contribute to undue influence in politics, raising concerns about corporate transparency and influence on public policy.
- FEB192025
AtriCure Inc spent $15,000 on lobbying efforts during 2023, according to data compiled by OpenSecrets from the Senate Office of Public Records. This disclosed expenditure highlights the company's engagement in political processes and attempts to influence policymaking.
-10
Political Contributions and Lobbying Efforts
April 30
The reported lobbying expenditure, though modest, represents AtriCure Inc's active engagement with political processes. From an anti-authoritarian perspective, such corporate political influence—even on a smaller scale—raises concerns about potential undue influence over regulatory and policy outcomes, thereby meriting a negative score.
- DEC312023
According to OpenSecrets, AtriCure Inc spent $53,500 on lobbying activities in 2023, indicating active engagement in influencing public policy.
-20
Political Contributions and Lobbying Efforts
April 30
The reported lobbying expenditure of $53,500 by AtriCure Inc demonstrates corporate efforts to influence political processes. From a left‑leaning anti‑fascist perspective, such corporate political spending can be viewed as a mechanism to protect and advance corporate interests, potentially at the expense of broader democratic accountability and marginalized communities.
- NOV142023
AtriCure, Inc. published its 2023 ESG Report highlighting a series of initiatives including recognition for diversity, equity, and inclusion (DEI) from NACD, strengthening of supply chain relationships through an annual Supplier Summit, and programs aimed at employee and community development.
+70
Labor Relations and Human Rights Practices
April 30
The ESG report underscores AtriCure's commitment to enhancing diversity, equity, and inclusion by earning a NACD DEI award, reflecting strong labor relations and human rights practices which align with progressive, anti-fascist values.
+60
Supply Chain Ethics
April 30
The report also outlines efforts to enhance supply chain ethics, including plans for an annual Supplier Summit to foster transparent and ethical dialogue with key business partners, supporting sustainable business practices.
- NOV012023
AtriCure, Inc. released its 2023 ESG report detailing its progressive initiatives including receiving the NACD Diversity, Equity & Inclusion Award, launching the Women’s Cardiac Health Awareness Program, and implementing robust labor practices. These steps demonstrate the company's commitment to ethical governance, sustainable business practices, and the advancement of diversity and inclusion.
+80
Business Practices and Ethical Responsibility
April 30
The ESG report outlines comprehensive efforts in ethical business practices and governance, including robust DE&I measures and sustainable strategies that align with progressive, anti-authoritarian values.
+70
Labor Relations and Human Rights Practices
April 30
The report emphasizes improvements in labor relations and human rights practices, notably through the recognition received for diversity and inclusion efforts and initiatives to support marginalized communities, which reflect a commitment to progressive labor practices.
- JAN012023
Atricure, Inc. has agreed to pay $3.76 million to resolve civil claims in a Medicare fraud case, with allegations that the company promoted unapproved uses of its cardiac devices, up-coded surgeries for inflated Medicare reimbursement, and provided kickbacks to healthcare providers.
-40
Business Practices and Ethical Responsibility
April 30
The settlement highlights serious ethical issues in Atricure's business practices. The company is accused of engaging in deceptive marketing of its medical devices by promoting unapproved procedures and advising on up-coding practices, which directly undermines regulatory standards and public trust. Such unethical practices harm vulnerable patients and misuse Medicare funds, aligning with broader concerns about corporate misconduct. This negative score reflects the company's failure to adhere to ethical business practices and its contribution to systemic abuse.
Atricure to pay $3.76M to resolve Medicare fraud allegations
- JAN012023
Atricure Inc. reached a $3.76 million settlement in a whistleblower class action lawsuit alleging fraudulent Medicare claims, unapproved device marketing, upcoding procedures, and kickbacks to healthcare providers.
-80
Business Practices and Ethical Responsibility
April 30
Atricure Inc. is accused of engaging in unethical and fraudulent business practices by submitting false Medicare claims, marketing devices for unapproved uses, advising hospitals to up-code procedures, and paying kickbacks. These actions represent a serious violation of ethical business practices and regulatory standards, undermining public trust in healthcare systems.
$3.76 Million Settlement reached in Whisteblower case with Atricure Inc
- FEB262019
On February 26, 2019, AtriCure, Inc. updated its supplier contracts to include clauses requiring suppliers to certify their adherence to the company's Business Partner Conduct Standards. In addition, the company initiated the drafting of its official Statement on Human Rights and Human Trafficking Policy to reinforce its commitment to ethical business practices and supply chain integrity under the UK Modern Slavery Act.
+80
Supply Chain Ethics
April 30
AtriCure's decision to revise supplier contracts to mandate certification of compliance with its Business Partner Conduct Standards, along with the move to draft an official Statement on Human Rights, demonstrates a proactive effort to ensure labor rights and ethical practices in its supply chain. This is a positive, anti-authoritarian step that aligns with modern standards against human trafficking and exploitation, thereby fostering greater corporate accountability and transparency.
PDF United Kingdom Modern Slavery Act Statement - AtriCure, Inc.
- FEB262019
On February 26, 2019, AtriCure, Inc. released its United Kingdom Modern Slavery Act Statement detailing enhanced measures to prevent slavery and human trafficking in its supply chain, including revised supplier contracts that require certification of compliance with its Business Partner Conduct Standards and initiatives to draft official Human Rights and Human Trafficking policies.
+70
Supply Chain Ethics
April 30
AtriCure’s proactive measures to revise supplier contracts and its commitment to developing official human rights and human trafficking policies directly address supply chain ethics. These actions align with enforcing labor standards and preventing modern slavery, which are positive steps in promoting ethical business practices.
PDF United Kingdom Modern Slavery Act Statement - AtriCure, Inc.
- FEB022010
Atricure, Inc. agreed to pay $3.76 million to resolve civil claims stemming from allegations that it promoted its surgical ablation devices for unapproved uses, advised hospitals to up-code surgical procedures to inflate Medicare claims, and paid kickbacks to healthcare providers.
-70
Business Practices and Ethical Responsibility
April 30
The settlement arises from allegations that Atricure engaged in a series of unethical business practices, including promoting unapproved medical device uses, advising hospitals to up-code procedures, and paying kickbacks. Such actions undermine ethical business practices and damage public trust, warranting a negative score within the Business Practices and Ethical Responsibility category.
Atricure to Pay U.S. $3.76 Million to Resolve Medicare Fraud Allegations
Alternatives
Corporation
5.15
Corporation
56.92
Corporation
0.00
Corporation
0.00
Abbott Park, United States
-41.63
Thousand Oaks, USA
13.57
Syria
11.25
Foster City, USA
1.64
Geneva, Switzerland
66.33
Vancouver, Canada
50.73
Industries
- 339113
- Surgical Appliance and Supplies Manufacturing
- 423450
- Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
- 621511
- Medical Laboratories